There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical, Inc. (RARE) and Co-Diagnostics Inc (CODX) with bullish sentiments.
Ultragenyx Pharmaceutical, Inc. (RARE)
In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx Pharmaceutical, Inc.. The company’s shares closed last Monday at $45.06, close to its 52-week low of $37.44.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 1.2% and a 40.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical, Inc. with a $80.13 average price target, which is a 53.2% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
Co-Diagnostics Inc (CODX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Co-Diagnostics Inc today and set a price target of $2. The company’s shares closed last Monday at $1.16, close to its 52-week low of $0.69.
Chen commented:
“Our 12-month price target is based on a comparable universe derived enterprise value-to-sales (EV/ Sales) multiple of 5.7x and projected sales of $0.36 per share for the next 12 months. Risks include, but are not limited to: (1) lower-than-projected uptake of products; (2) inability to maintain regulatory compliance; and (3) inability to develop additional products targeting segments beyond infectious disease in developing markets. Co-Diagnostics, Inc.”
According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -21.9% and a 25.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
Co-Diagnostics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $2.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
